Systemic Levels of Anti-VEGF: What Available Data Reveal

Show Description +

Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.

Posted: 1/16/2014

Systemic Levels of Anti-VEGF: What Available Data Reveal

Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.

Posted: 1/16/2014

Please log in to leave a comment.

Comments

majid kheirkhahr

12 years ago

amazing.

More in Retina

Observation vs. Vitrectomy for Floaters

Kyle Kovacs, MD; Matthew Starr, MD; and Neda Valikodath, MD

IL-6 Inhibition in Diabetic Macular Edema

Arshad M. Khanani, MD, MA, FASRS, and Roger A. Goldberg, MD

Phase 3 Clinical Trial Results for OTX-TKI

Patricio G. Schlottmann, MD

Using OCT and AI to Evaluate Uveitis

Parisa Emami-Naeini, MD, MPH